Corticosteroids produced body

We included five RCTs involving 576 people. The trials were largely at low risk of bias , but we considered the quality of the evidence from these trials as moderate to low, largely due to imprecision from small sample sizes. Two out of the five trials reported on improvement in nerve function at one year. These two trials compared prednisolone with placebo . One trial , with 84 participants, treated mild sensory impairment of less than six months' duration, and the other, with 95 participants, treated nerve function impairment of 6 to 24 months' duration. There was no significant difference in nerve function improvement after 12 months between people treated with prednisolone and those treated with placebo . Adverse events were not reported significantly more often with corticosteroids than with placebo . The other three trials did not report on the primary outcome measure. One (334 participants) compared three corticosteroid regimens for severe type 1 reactions. No serious side effects of steroids were reported in any participant during the follow-up period. Another trial (21 participants) compared low-dose prednisone with high-dose prednisone for ulnar neuropathy. Two participants on the higher dose of prednisone reported adverse effects . The last (42 participants) compared intravenous methylprednisolone and oral prednisolone with intravenous normal saline and oral prednisolone. The trial found no significant differences between the groups in the occurrence of adverse events.

Because of these side effects, doctors frequently choose safer medications, such as the 5-ASA drugs and antibiotics, as initial therapy. But there are a number of ways to reduce the risk of developing side effects. These include rapid but careful tapering off of steroids; alternate-day dosing; rectally applied corticosteroids; and rapidly metabolized corticosteroids such as budesonide (described above). To help prevent osteoporosis, many doctors routinely prescribe calcium supplements as well as multivitamins that contain vitamin D. Another option is the use of bisphosphonates, such as risedronate (Actonel®) and alendronate (Fosamax®). These compounds, which have been shown to help avert bone loss, are effective in treating and preventing steroid-induced osteoporosis.

Certain drugs such as troleandomycin (TAO), erythromycin ( Ery-Tab , EryPed 200), and clarithromycin ( Biaxin ) and ketoconazole ( Nizoral ) can reduce the ability of the liver to metabolize (breakdown) corticosteroids and this may lead to an increase in the levels and side effects of corticosteroids in the body. On the other hand, phenobarbital, ephedrine , phenytoin ( Dilantin ), and rifampin ( Rifadin , Rimactane ) may reduce the blood levels of corticosteroids by increasing the breakdown of corticosteroids by the liver. This may necessitate an increase of corticosteroid dose when they are used in combination with these drugs.

Subgroup analyses for causative organisms showed that corticosteroids reduced mortality in Streptococcus pneumoniae ( S. pneumoniae ) meningitis ( RR , 95% CI to ), but not in Haemophilus influenzae ( H. influenzae ) or Neisseria meningitidis ( N. meningitidis ) meningitis. Corticosteroids reduced severe hearing loss in children with H. influenzae meningitis ( RR , 95% CI to ) but not in children with meningitis due to non- Haemophilus species.

Corticosteroids produced body

corticosteroids produced body

Subgroup analyses for causative organisms showed that corticosteroids reduced mortality in Streptococcus pneumoniae ( S. pneumoniae ) meningitis ( RR , 95% CI to ), but not in Haemophilus influenzae ( H. influenzae ) or Neisseria meningitidis ( N. meningitidis ) meningitis. Corticosteroids reduced severe hearing loss in children with H. influenzae meningitis ( RR , 95% CI to ) but not in children with meningitis due to non- Haemophilus species.

Media:

corticosteroids produced bodycorticosteroids produced bodycorticosteroids produced bodycorticosteroids produced bodycorticosteroids produced body